{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:56:42Z","timestamp":1788883002549,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.leukres.2017.03.003","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T16:05:10Z","timestamp":1488816310000},"page":"109-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much"],"prefix":"10.1016","volume":"57","author":[{"given":"Robert Peter","family":"Gale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Opelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.03.003_bib0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"11","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.leukres.2017.03.003_bib0010","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2017.03.003_bib0015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/leu.2011.224","article-title":"Commentary: Does immune suppression increase risk of developing acute myeloid leukemia","volume":"26","author":"Gale","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.03.003_bib0020","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bjc.6601219","article-title":"Cancer risk following organ transplantation: a nationwide cohort study in Sweden","volume":"89","author":"Adami","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2017.03.003_bib0025","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.leukres.2017.03.003_bib0030","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1600-6143.2007.01736.x","article-title":"Cancer incidence among Canadian kidney transplant recipients","volume":"7","author":"Villeneuve","year":"2007","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.leukres.2017.03.003_bib0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.03.003_bib0040","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/bmt.2016.183","article-title":"Is there really a specific graft-versus-leukaemia effect","volume":"51","author":"Gale","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2017.03.003_bib0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1667\/RR2892.1","article-title":"The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950\u20132001","volume":"179","author":"Hsu","year":"2013","journal-title":"Radiat. Res."},{"key":"10.1016\/j.leukres.2017.03.003_bib0050","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.03.003_bib0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter STOP imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2017.03.003_bib0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetected disease","volume":"32","author":"Rousselot","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.03.003_bib0065","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.03.003_bib0070","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.03.003_bib0075","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2003-11-3938","article-title":"Defective DNA mismatch repair in acute myeloid leukemia\/myelodysplastic syndrome after organ transplantation","volume":"104","author":"Offman","year":"2004","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T08:05:14Z","timestamp":1601712314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617300723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":15,"alternative-id":["S0145212617300723"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.03.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}